8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Eli Lilly reports 39% revenue growth and raises 2026 guidance
Filed with the SEC on · Summarized by InvestorsBot
Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39% from a year earlier, with reported EPS of $7.22 and non-GAAP EPS of $7.48; Mounjaro and Zepbound were the main growth drivers. The company raised 2026 revenue guidance to $91 billion-$92 billion from $85 billion-$87 billion, while updated non-GAAP EPS guidance is $35.00-$36.00 after $4.57 per-share of acquired in-process research and development charges tied to recent business development activity.